Search all ALPCO products, resources, and website information

Clinical Research
New: Calprotectin Immunoturbidimetric Assay will take your testing to the next level. Learn more.ALPCO has been serving the needs of clinical researchers and clinical diagnostics labs for over 30 years, and we now offer a broad product menu of proprietary automated sample-to-answer platforms. We’re ...
AACC 2023
Skip the crowd and reserve your time for a demonstration or individual meeting with a member of our team.Stop by Booth #2547 Ask About Our Targeted Solutions for Your GI Testing.Customized solutions for your calprotectin testing needs.GI SOLUTIONSEnsure AccuracyNew! Calprotectin Immunoturbidimetric...
Explore ALPCO's Diverse Products for Gastroenterology Research
Explore ALPCO's Diverse Products for Gastroenterology Research  AGA Guidelines: Calprotectin and C-Reactive Protein Monitoring for the Management of Crohn’s Disease   Download ou infograhpic prepared by ALPCO and gain a comprehensive overview of the American Gastroenterological Association (...
Alpco Home Page
New: Calprotectin Immunoturbidimetric Assay will take your testing to the next level. Learn more.Supporting your work with life science and clinical testing productsVIEW ALL LIFE SCIENCE PRODUCTSVIEW ALL CLINICAL DIAGNOSTIC PRODUCTS
Differentiating Gastrointestinal Pathogens from IBD and IBS
Gastrointestinal (GI) disorders such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), as well as infections from GI pathogens can present very similar symptoms. A host of tests have been developed to aid in the differentiation between IBD and IBS, such as calprotectin and lact...
Stool-Based Biomarkers to Differentiate Between IBD and IBS
What are IBD and IBS? Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two different gastrointestinal tract issues affecting millions of people every day. Although there is some overlap between symptoms of IBD and IBS, differences still remain in regards to pathologies, risks...
New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD to be Launched at Digestive Disease Week®
We are excited to announce that we will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this release are the Zonulin Stool ELISA and Zonulin Serum ELISA to aid in the study of gut permeability and celiac dis...
ALPCO to Exhibit at the AACC’s 70th Annual Scientific Meeting and Clinical Lab Expo
July 25, 2018 ALPCO will exhibit at the AACC’s 70th Annual Clinical Lab Expo July 31-August 2, 2018 in Chicago, IL. The company will promote a number of tools to help research and improve clinical outcomes as well as increase laboratory efficiency. Among these tools are new and upcoming additi...
Now Available: 510(k) Cleared Fecal Calprotectin ELISA
ALPCO received 510(k) clearance from the US FDA for its new fecal Calprotectin Chemiluminescence ELISA test. The ALPCO Calprotectin Chemiluminescence ELISA’s superior clinical accuracy will enable clinical laboratories to provide the most accurate results to gastroenterologists facing the cha...
Why Clinical Specificity is Important for FDA Cleared Fecal Calprotectin Tests
The Importance of Clinical Specificity: A Review of FDA Cleared Fecal Calprotectin Tests Download Selecting the right fecal calprotectin test for your clinical laboratory to run in-house or send out can be a difficult task to accomplish, especially when there are multiple FDA cleared options...
ALPCO’s Calprotectin Validation Assistance Program
Whether your clinical laboratory is transitioning over to the ALPCO Calprotectin Chemiluminescence ELISA from another calprotectin assay or starting to run the test in-house for the first time, validation is the most crucial step in the assay implementation process. We understand that validating a n...
Managing Calprotectin as a Send Out?
While sending out for calprotectin testing offers some cost and convenience advantages when volumes are very low, bringing the process in-house allows for the opportunity to control costs, turnaround time, and quality. Considering costs and potential revenue, the volume at which in-house calprotecti...
Enhance Your Lab’s Molecular GI Portfolio
Molecular GI testing for bacteria such as salmonella, vibrio, and E. coli, and viral pathogens including norovirus and rotavirus, is instrumental in the diagnosis and treatment of infection and dysbiosis. In addition, many gastrointestinal disorders often require protein biomarker tests to aid in ac...
GI Testing
Calprotectin Chemiluminescence ELISA (80-CALPHU-CH01) The Calprotectin Chemiluminescence ELISA is an in vitro diagnostic chemiluminescent assay intended for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human sto...
Differentiating IBD from IBS with Fecal Calprotectin Testing
In an effort to improve patient care, an increasing number of gastroenterologists are using fecal calprotectin levels as a first step in the diagnosis of IBD versus IBS. ALPCO tests enable clinicians to accurately assess patients via calprotectin and quickly start patients on the right treatment pat...
High Throughput Calprotectin Testing with ALPCO Immunoturbidimetric Assay
Maximize lab efficiency with ALPCO's calprotectin immunoturbidimetric assay. Leverage existing analyzers, ensure accurate results, and improve turnaround times. 
AutoPlex Automated Multiplex Biomarker Analysis
ALPCO’s automated multiplex assay, AutoPlex GI Panel, provides sensitive and accurate measurement of up to 5 GI biomarkers in human stool samples. The panel combines the workflow advantages of multiplexing with the proven reliability of traditional chemiluminescence sandwich immunoassays to enable b...
ALPCO Releases STELLUX® Chemiluminescent Human Intact Proinsulin ELISA
ALPCO announced in a press release on February 18, 2014 that the company has launched their new STELLUX® Chemiluminescent Human Intact Proinsulin ELISA, the latest assay to be launched in the company’s STELLUX® Chemiluminescent product line. The new Human Intact Proinsulin ELISA features a broad dyn...
ALPCO to Feature New STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and Young Investigators Travel Grant Program at ADA’s 78th Scientific Sessions
June 19, 2018 ALPCO, a leading producer of research and clinical immunoassays, announced it will showcase its new STELLUX® Chemi Active GLP-1 (7-36) amide ELISA at the American Diabetes Association’s 78th Scientific Sessions June 23-25, 2018 in Orlando, FL.  This new addition to the STELLUX® Chem...
ALPCO's New FDA Cleared 25-OH Vitamin D Total ELISA Provides Option for Hospitals and Smaller Clinical Labs to Bring Affordable Testing In-House
ALPCO announced in a press release on January 22, 2014 that their test portfolio for clinical and hospital laboratory customers has expanded to include a new FDA 510(k) cleared 25-OH Vitamin D Total ELISA. The growth in 25-OH Vitamin D testing has been a challenge for clinical and hospital labora...
Plate Washing Technique
Recommendations for hand washing and drying an ELISA plate. https://www.youtube.com/watch?v=6gkUj5xn8_g&feature=youtu.be
ALPCO Releases New Chemiluminescent Human C-peptide ELISA
ALPCO announced the launch of its new STELLUX® Chemiluminescent Human C-peptide ELISA on December 5, 2014. This highly characterized assay measures C-peptide requiring only 50 µL of human serum, plasma or cell culture supernatant. The ELISA exhibits greater sensitivity and a broader dynamic range co...
Complement System Solutions for Drug Development and Clinical Research
Datasheet: Complement System Immunoassays Download The complement system is essential to innate immunity which protects from chronic, autoimmune, and infectious disease. There are three distinct pathways of complement activation: classical, lectin/MBL, and alternative. Each leads...